Proceeds to advance lead immunology program COL-5671, a potential first-in-class, oral once-daily therapy, across a range of auto-immune indications
Leuven, Belgium. April 28, 2026 - Coultreon Biopharma (formerly Onco3R Therapeutics), a biotechnology company developing best-in-class therapies in immunology, today announced the closing of an oversubscribed $125 million Series A financing round. Sofinnova Investments led the financing round, with Forbion and Novo Holdings as co-leads, joined by Galapagos, Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund and Finchley Healthcare Ventures.
Autoimmune diseases remain a significant area of unmet medical need, with many patients cycling through therapies that fail to deliver durable control of inflammation or disease progression. Coultreon's approach is rooted in more than 15 years of research into salt-inducible kinases (SIKs), a family of proteins that regulate key inflammatory pathways. The company has identified SIK3 as a central driver of pathogenic immune signaling, offering a differentiated and potentially more targeted approach to treating autoimmune disease.
The financing will support the further clinical development of Coultreon's lead immunology program, COL-5671 (formerly O3R-5671), a highly selective, ...
